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ORIGINAL ARTICLE
Genetic variants affecting cross-sectional lung
function in adults show little or no effect on
longitudinal lung function decline
Catherine John,1 María Soler Artigas,1 Jennie Hui,2,3,4,5 Sune Fallgaard Nielsen,6
Nicholas Rafaels,7 Peter D Paré,8 Nadia N Hansel,9 Nick Shrine,1 Iain Kilty,10
Anders Malarstig,11 Scott A Jelinsky,10 Signe Vedel-Krogh,6 Kathleen Barnes,7
Ian P Hall,12 John Beilby,2,3,4 Arthur W Musk,4,5,13,14 Børge G Nordestgaard,6
Alan James,4,14,15 Louise V Wain,1,16 Martin D Tobin1,16
ABSTRACT
Background Genome-wide association studies have
identiﬁed numerous genetic regions that inﬂuence cross-
sectional lung function. Longitudinal decline in lung
function also includes a heritable component but the
genetic determinants have yet to be deﬁned.
Objectives We aimed to determine whether regions
associated with cross-sectional lung function were also
associated with longitudinal decline and to seek novel
variants which inﬂuence decline.
Methods We analysed genome-wide data from 4167
individuals from the Busselton Health Study cohort, who
had undergone spirometry (12 695 observations across
eight time points). A mixed model was ﬁtted and
weighted risk scores were calculated for the joint effect
of 26 known regions on baseline and longitudinal
changes in FEV1 and FEV1/FVC. Potential additional
regions of interest were identiﬁed and followed up in
two independent cohorts.
Results The 26 regions previously associated with
cross-sectional lung function jointly showed a strong
effect on baseline lung function (p=4.44×10−16 for
FEV1/FVC) but no effect on longitudinal decline
(p=0.160 for FEV1/FVC). This was replicated in an
independent cohort. 39 additional regions of interest
(48 variants) were identiﬁed; these associations were
not replicated in two further cohorts.
Conclusions Previously identiﬁed genetic variants
jointly have a strong effect on cross-sectional lung
function in adults but little or no effect on the rate of
decline of lung function. It is possible that they inﬂuence
COPD risk through lung development. Although no
genetic variants have yet been associated with lung
function decline at stringent genome-wide signiﬁcance,
longitudinal change in lung function is heritable
suggesting that there is scope for future discoveries.
INTRODUCTION
Reduction of FEV1 relative to FVC deﬁnes COPD,
one of the leading causes of death worldwide.
Measures of lung function are also important pre-
dictors of morbidity and mortality in the general
population.1–3 While environmental factors, par-
ticularly smoking, impact lung function, genetic
variation is also a major determinant.4
Genome-wide association studies (GWAS) to date
have identiﬁed numerous regions associated with
lung function measured at a single point in time
(ie, cross-sectional lung function).5–9 The lung
function attained at a given time point in adult-
hood will be inﬂuenced by factors that affect either
the development of lung function in earlier life or
the rate of subsequent decline in lung function or
both. Both cross-sectional lung function and longi-
tudinal change in lung function are heritable.
Although heritability estimates for longitudinal
decline in lung function range between 10% and
39%,10 the individual genetic determinants have
yet to be deﬁned. Identifying the responsible genes
could provide a promising route for intervention in
COPD, since this is typically diagnosed well after
lung function has reached its peak and modifying
its further decline could prove to be a feasible
therapeutic option.
The objectives of our study were as follows:
(1) to examine the association with longitudinal
change for those regions previously identiﬁed as
signiﬁcantly associated with cross-sectional FEV1 or
FEV1/FVC and (2) to seek novel variants which
Key messages
What is the key question?
▸ Do genetic regions associated with cross-sectional
lung function also show association with rate of
decline?
What is the bottom line?
▸ Twenty-six regions associated with cross-
sectional lung function in adults—many of them
associated with COPD risk—were not associated
with rate of decline in lung function.
Why read on?
▸ These ﬁndings provide an important insight
into the possible pathways through which
known genetic regions inﬂuence lung function
and risk of COPD.
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reach genome-wide signiﬁcance for association with longitudinal
change in lung function, using a cohort with multiple lung func-
tion measurements over an extended period of up to 40 years
and an imputation panel which provides dense coverage of both
common and low-frequency variants.
METHODS
Discovery data source and study population
The Busselton Health Study (BHS) is a longitudinal health
survey that began in 1966 in the town of Busselton in the south-
western region of Western Australia. In 1994/1995, a cross-
sectional community follow-up study was undertaken where
blood was taken for DNA extraction. A sample of 1468 indivi-
duals with European ancestry were genotyped using the
Illumina 610-Quad BeadChip (BHS1) and subsequent genotyp-
ing was carried out on an independent group of 3407 indivi-
duals with European ancestry using Illumina 660W-Quad
(BHS2). Spirometric measures of FEV1 and FVC were assessed.
From 1966 to 1978 (ﬁve surveys), FEV1 and FVC were mea-
sured using a McDermott dry spirometer (Pneumoconiosis
Research Unit, Penarth, UK) and recorded as the highest values
from three measurements (provided that two recordings were
within 10% of each other). Wedge spirometers (Vitalograph,
Buckingham, UK) were used in the 1981 survey and pneumo-
tachograph spirometers (Welch Allyn, Skaneateles Falls,
New York, USA) were used in 1994/1995.11 12 FEV1 and FVC
were measured in 2005 using Medgraphics pneumotachograph
spirometers and recorded with BreezeSuite 6.2 (Medical
Graphics, St Paul, USA).13 From 1981 onwards, spirometric
measurements met American Thoracic Society guidelines (52%
of the total number of measurements).14 15
Demographic details and mean lung function measurements
for this and replication cohorts are shown in table 1.
Observations prior to age 25 were excluded from both discov-
ery and replication analyses.16
Genotype quality control and imputation
Genotype data from BHS1 and BHS2 samples were merged and
quality control (QC) was undertaken for both variant quality
and sample quality. Prior to imputation, variants were excluded
if they had a call rate <95%, deviated from Hardy-Weinberg
equilibrium (p<10−6) or had a minor allele frequency (MAF) of
<1% (100 240 variants). Individuals were excluded if their call
rate was <95%, if their submitted gender and gender inferred
by genotype were inconsistent, if they were a duplicate or if
they were an outlier for heterozygosity (169 individuals).
Principal components analysis was used to exclude individuals
of non-European ancestry (those at least four SDs away from
the mean for at least one of the ﬁrst two principal components)
(27 individuals). Analysis of identity by descent (IBD) was com-
pared with the reported pedigree; any inconsistencies were
reviewed and individuals were excluded as appropriate (40 indi-
viduals; see online supplementary material for further details).
QC was undertaken using PLINK V.1.07 (Purcell S; http://pngu.
mph.harvard.edu/purcell/plink),17 EIGENSOFT (V.4.2)18 19 and
R V.2.15 (R Core Team; http://www.R-project.org).
Imputation was undertaken using the 1000 Genomes Project
reference panel (1000G Phase I Integrated Release V.3 (March
2012)).20 Chunking was performed using ChunkChromosome,
phasing using MaCH (V.1.0.18)21 and imputation using
Minimac (V.2012.10.3).22 Variants where imputation quality (r2)
was <0.3 or MAF <1% were excluded.
Phenotype QC and analysis
Data on age and smoking were checked for consistency over
time. Where possible, missing data on height or smoking at
one time point were imputed to be the same as that at the
nearest time point (407 data items imputed in total). Otherwise,
observations with missing data on lung function, age or height
or where FEV1 was greater than FVC were excluded from the
analysis. After phenotype and genotype datasets were merged,
and after samples failing genotype QC were excluded, 12 863
observations for 4170 individuals and up to eight time points
were available prior to further phenotype QC.
A time variable was created for each observation, determined
by the difference between the age of the individual at that obser-
vation and their age at the ﬁrst time point for which data were
available on that individual. Family was deﬁned based on IBD,
such that all individuals in a family were related (IBD >0.2) with
at least one other person in the family. A full model with age,
age2, height, height2, sex and time as ﬁxed effects and an inter-
cept varying per individual, an intercept varying per family and a
slope for time varying per individual as random effects was ﬁtted
to the data for each trait (FEV1, FEV1/FVC and FVC).
Additionally, another four models were ﬁtted, excluding the
random intercept varying per family, the random slope for time
varying per individual and age2 and height2 one at a time and
comparing with the full model using Akaike information criter-
ion and Bayesian information criterion. The ﬁnal model included
all the terms in the full model, except for age2 as this did not
improve the ﬁt of the model (see online supplementary table S1).
Outlying observations (with residuals more than four SDs away
from the mean) for any of the three traits analysed, FEV1, FEV1/
FVC and FVC, were then excluded from the analysis (168 obser-
vations and three individuals excluded). This resulted in 12 695
observations for 4167 individuals and up to eight time points
included in the ﬁnal analysis. The mean number of measurements
per participant was three (see online supplementary ﬁgure S1)
and the mean length of follow-up was 15.5 years.
Genetic risk scores
Previously published studies identiﬁed variants in 26 regions sig-
niﬁcantly associated with cross-sectional FEV1 and/or FEV1/
FVC.5–8 We compared the effect size estimates for these 26 var-
iants in BHS with the previously published effect size estimates.
A weighted risk score was calculated for the joint effect of these
26 regions on baseline FEV1 and FEV1/FVC as well as on
change over time in both traits. The single-nucleotide poly-
morphisms (SNPs) included in this analysis are shown in the
online supplementary table S2.
Unbiased (winner’s curse-free) effect sizes, as calculated previ-
ously but excluding any data from BHS,8 were used as weights
for the 26 variants in the risk score calculations (weights, range
0.2–2.57, provided in online supplementary table S3). The
number of risk alleles for each variant was multiplied by its cor-
responding weight and then summed across variants in order to
obtain the risk score for each individual and to create the risk
score variable. This risk score variable was then added to the
ﬁnal model described above, together with the risk score by
time interaction, in order to obtain both the effect on baseline
and on change over time.
Genome-wide association analysis and selection of variants
for follow-up analysis
The effect of individual genetic variants (which included SNPs
and indels) on the rate of decline in FEV1, FEV1/FVC and FVC
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was tested by adding a variant and variant-by-time interaction
into the ﬁnal phenotypic model described above. Using this
model, genome-wide association analyses were undertaken for
29 798 550 variants assuming an additive genetic effect.
Genomic control was subsequently applied (genomic inﬂation
factors for slope change were 1.04, 1.03 and 1.06 for FEV1,
FEV1/FVC and FVC, respectively).
23
Figure 1 illustrates our criteria for selection of variants for
follow-up analysis. We identiﬁed variants potentially associated
(p<5×10−6 taken as suggestive of association) with longitudinal
FEV1, FEV1/FVC or FVC. We deﬁned regions of association
around the most strongly associated variant (sentinel variant)
±500 kb. We examined region plots to assess support from
neighbouring variants and cluster plots for the closest genotyped
variant to the sentinel variant in order to rule out associations
driven by genotyping errors. Regions were selected for
follow-up if they had at least one variant (either the top variant
or a proxy in linkage disequilibrium with r2 >0.2) with imput-
ation quality >0.7 and p value <5×10−5.
Within each region, we selected variants for follow-up ana-
lysis as follows: (1) the sentinel variant, (2) a second variant in
the region with imputation quality >0.7 and p value <5×10−5
where the sentinel variant had imputation quality <0.7 and (3)
for regions in which variants showed nominal interaction with
smoking (p <0.05 for interaction term based on a Z-test
between ever-smokers and never-smokers), the most signiﬁcant
variant in the group (ever-smokers or never-smokers) where the
sentinel variant’s effect size estimate was largest.
Sensitivity analyses were also undertaken for the regions
which met the criteria for follow-up analysis to assess whether
their effect could be mediated through smoking behaviour. The
same model was ﬁtted, with an additional term for smoking
status (ever-smoked or never-smoked), and effect sizes were
compared.
Estimations of power were also obtained for the discovery of
new signals and for detection of associations with the 26 var-
iants previously reported to be associated with cross-sectional
lung function (see online supplementary materials).
Replication
Follow-up analyses for the 39 new regions potentially associated
with longitudinal change were undertaken in the Copenhagen
City Heart Study (CCHS), a prospective study of a random
sample of the Danish general population, aged ≥20 years,
drawn using the Danish Civil Registration System (n=9016)
who had lung function measurements at up to three time points
between 1976 and 1994,24 with a further measurement in
2001–03.25 Follow-up was also undertaken in the Lung Health
Study (LHS), a North American cohort of smokers with mild
airﬂow limitation who had annual lung function measurements
for 5 years (n=3502).26 Risk score analyses with the previously
reported 26 variants were also undertaken in CCHS.5–8 QC
procedures (including inspection of cluster plots) were applied
and the same model was ﬁtted as for BHS, but without adjust-
ment for relatedness, given that there were no related indivi-
duals. Demographic details and mean lung function
measurements for CCHS and LHS are shown in table 1.
All risk score and association analyses were undertaken in R
using the package ‘lme4’ (Bates D, Maechler M, Bolker B, et al;
http://CRAN.R-project.org/package=lme4).
RESULTS
Known regions: calculation of risk scores and replication
Comparison of effect sizes for cross-sectional lung function and
longitudinal change and weighted risk score analyses showed
that 26 variants previously identiﬁed as associated with cross-
sectional lung function were not signiﬁcantly associated with
longitudinal change in our cohort.
There was a strong correlation between estimated SNP effects
on baseline lung function in BHS and in published estimates6–8
for both FEV1 (r=0.76) and FEV1/FVC (r=0.78). However,
estimated SNP effects on change in FEV1 and FEV1/FVC were
weakly correlated with published estimates for the respective
cross-sectional trait (ﬁgure 2 and online supplementary ﬁgure
S2).
A weighted risk score was calculated for the joint effect of
these 26 regions on baseline FEV1 and FEV1/FVC as well as
change over time in both traits. This showed a strong effect on
baseline FEV1 (p=9.75×10
−12) and FEV1/FVC
(p=4.44×10−16) but no effect was observed on change over
time for either FEV1 (p=0.409) or FEV1/FVC (p=0.160)
(table 2).
In silico data were available for eight known variants in
CCHS and genotyping was undertaken for the remaining 18
variants. All of these passed QC procedures. They showed a
joint effect similar to that seen in BHS: a strong association
with baseline measurement (p=4.45×10−10) but no association
with change over time in FEV1/FVC (p=0.302) and strong
association with baseline measurement (p=8.92×10−7) but
only borderline association with change over time for FEV1
(p=0.030) (table 2).
New signals: discovery and replication
Genome-wide analysis identiﬁed 56 independent regions which
were associated with decline in FEV1, FEV1/FVC and/or FVC at
a signiﬁcance threshold of p<5x10−6. Thirty-nine of these
regions (48 variants) were selected for follow-up based on the
criteria described under ‘Methods’: 11 regions (13 variants) for
change in FEV1, 15 regions (19 variants) for change in FVC and
13 regions (16 variants) for change in FEV1/FVC. These are
shown in table 3. The most signiﬁcantly associated variant
Table 1 Descriptive characteristics of cohorts included in discovery and follow-up (age and lung function measurements as at first time point)
Study
No. of
participants
Women,
%
Ever-smokers,
%
Mean age,
years (SD)
Age
range,
years
Mean FEV1,
L (SD)
Mean FVC,
L (SD)
Mean FEV1/
FVC (SD)
Mean annual
change in
FEV1, mL (SD)
Range of
annual
change in
FEV1, mL
BHS 4167 56.1 48.8 38.6 (10.6) 25–82 3.35 (0.87) 4.26 (1.04) 0.79 (0.08) −27.2 (20.3) −150 to 90
CCHS 9016 55.6 75.7 46.4 (11.1) 25–85 2.98 (0.91) 3.69 (1.08) 0.81 (0.09) −30.1 (29.7) −260 to 220
LHS 3502 36.6 100 48.6 (6.7) 35–62 2.77 (0.63) 4.3 (0.94) 0.65 (0.07) −51.0 (55.6) −338 to 168
BHS, Busselton Health Study; CCHS, Copenhagen City Heart Study; LHS, Lung Health Study.
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(rs6502247) showed an effect of 3.93 mL/year on decline in
FEV1 (p=3.23×10
−9).
Effect size estimates for these variants were not attenuated
after adjusting for smoking status and no variant-by-smoking
interaction met a Bonferroni-corrected threshold for the
number of regions tested (p<1.3×10−3).
De novo genotyping of all 48 variants was undertaken in
CCHS. Where genotyping failed, tags were identiﬁed, if pos-
sible. In total, 34 variants in 30 independent regions passed QC
procedures (including the inspection of cluster plots) and 14
failed. The analysis included 9016 individuals with up to four
time points (25 796 observations). None of these 34 variants
showed replicated association with change in lung function
(using a signiﬁcance threshold of p<0.0016, representing a
Bonferroni correction for 30 independent regions with α=0.05)
(see online supplementary table S4).
Thirty-one variants (in 26 of the 39 regions) for which in
silico data were available were also followed up in LHS. None
of these SNPs showed signiﬁcant association with lung function
decline in LHS (using a signiﬁcance threshold of p<0.0019,
representing a Bonferroni correction for 26 independent
regions with α=0.05) (see online supplementary table S5).
Results from both CCHS and LHS are shown in the online
supplementary materials. In total, 21 variants were analysed in
both follow-up studies, of these, 14 had the same direction of
effect as BHS after meta-analysing results from CCHS and LHS
(p=0.095).
For sentinel variants in regions previously reported to show
suggestive evidence of association with longitudinal lung func-
tion (though none met genome-wide signiﬁcance and replicated
in previous papers), we assessed association with FEV1, FVC
and/or FEV1/FVC in our data.
26–28 Of these 51 variants,10
showed nominal evidence of association with at least one of the
lung function traits either in the whole cohort or in one of the
smoking subgroups. However, none were signiﬁcant after cor-
rection for multiple testing (using a threshold of p<9.8×10−4)
(see online supplementary table S6).
DISCUSSION
We analysed the joint effect of regions previously associated
with cross-sectional lung function on longitudinal change in
the general population, and undertook a GWAS to identify
new signals associated with longitudinal change. Regions pre-
viously identiﬁed as signiﬁcantly associated with cross-
sectional FEV1 and/or FEV1/FVC
5–8 were jointly strongly
associated with baseline measurements in both discovery
(BHS) and replication (CCHS) cohorts. However, although
many of these variants have previously shown association with
COPD risk (TNS1, RARB, FAM13A, GSTCD, HHIP, HTR4,
ADAM19, AGER, GPR126, C10orf11, THSD4),29–33 we have
shown that they are not associated with change in FEV1 or
FEV1/FVC over time in our cohorts. We identiﬁed novel var-
iants associated with decline in lung function in BHS which
did not replicate in either a general population cohort
(CCHS) or a cohort of smokers with mild lung function
impairment (LHS).
A key strength of our study design is the improved coverage
of both common and low-frequency variants achieved through
imputation in the 1000 Genomes Project reference panel,20
compared with previous studies of longitudinal lung function
Figure 1 Flow chart showing the selection of variants for follow-up analysis. LD, linkage disequilibrium.
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which have used HapMap reference panels.26 27 34 Another
strength is the high number of lung function measurements in
BHS: up to eight measurements over a range of up to 40 years.
This is longer than other published studies, including most of
the individual studies in a meta-analysis by Tang et al,34 which
included a portion of our dataset. Our study also adds value as
it is the ﬁrst to calculate risk scores for longitudinal lung func-
tion. Nevertheless, such a long follow-up period brings some
challenges. Spirometry equipment changed over time and the
earlier surveys in BHS were performed before protocols for
standardisation of spirometry were published.11 14 15 In add-
ition, repeated measurements over a number of years could train
participants in optimal technique and underestimate decline in
lung function. The detection of known associations with cross-
sectional lung function provides some reassurance regarding the
extent of any potential measurement error in lung function
measurement.
The biggest challenge we faced was the availability of large
sample sizes for well-characterised longitudinal measures of lung
function. The sample size, in combination with possible
Figure 2 Representations showing the (A) correlation between estimated single-nucleotide polymorphism (SNP) effects on baseline FEV1 in
Busselton Health Study (BHS) and published estimates, (B) correlation between estimated SNP effects on change in FEV1 in BHS and published
estimates of SNP effects on cross-sectional FEV1, (C) correlation between estimated SNP effects on baseline FEV1/FVC in BHS and published
estimates and (D) correlation between estimated SNP effects on change in FEV1/FVC in BHS and published estimates of SNP effects on
cross-sectional FEV1/FVC (the correlation shown in (D) was reduced by excluding rs2070600, a non-synonymous coding SNP in AGER which had an
outlying result (see online supplementary ﬁgure S2)). o, SNP signiﬁcantly associated with cross-sectional measures of the trait under examination
(FEV1 in (A) and (B); FEV1/FVC in (C) and (D)) in prior literature. x, SNP signiﬁcantly associated with cross-sectional measures of the other trait
(FEV1/FVC in (A) and (B); FEV1 in (C) and (D)) in prior literature.
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measurement error, may have limited our ability to identify indi-
vidual variants which reach stringent genome-wide signiﬁcant
levels and replicate. However, our study will have had much
greater power to detect longitudinal effects of aggregate risk
scores comprised of the 26 variants previously reported to be
associated with cross-sectional lung function. We did not
examine risk scores for FVC, as at the time of the analyses there
were no published associations with FVC, and our focus was on
the determinants of obstructive lung disease. It is possible there-
fore that there are genetic associations with change in FVC over
time which we did not identify. We did not undertake analyses
stratiﬁed by sex, for reasons of power. However, effect estimates
were adjusted for sex. We did not adjust for smoking in the
primary analysis, since the analysis also had potential to high-
light novel signals for smoking behaviour. We undertook sensi-
tivity analyses to assess whether any top signals could be
mediated by smoking behaviour. The signals were not attenu-
ated after adjustment for smoking. However, this was based on
binary smoking status and there remains potential for incom-
plete adjustment.
Our study—the ﬁrst to our knowledge to examine risk scores
for change in lung function over time—complements existing
studies which have sought individual SNP associations,26–28
including a large meta-analysis of longitudinal lung function.34
The meta-analysis by Tang et al34 (concurrent with our study)
incorporated data from 27 349 individuals from 14 population-
based cohorts (including a subset of 1009 individuals from
BHS) and identiﬁed evidence for two novel regions associated
with rate of change in FEV1. However, these did not replicate
in two further cohort studies (including LHS). The authors
noted that the number of lung function measurements and dur-
ation of follow-up varied considerably between studies included
in the discovery phase and may have affected their ability to
detect associations. The failure to replicate novel associations
may relate to lack of power or, given that the larger replication
cohort in their study (LHS) was composed of smokers with
mild COPD, may indicate that the genetic determinants of lung
function decline in those with COPD differ from those in
healthy individuals.34
Similarly, a GWAS examining change in FEV1% predicted (in
a cohort of smokers with mild lung function impairment from
LHS) identiﬁed two regions reaching genome-wide signiﬁcance
which did not replicate in four general population cohorts or in
a cohort with moderate-to-severe COPD. The authors suggested
that regions which modify the effect of cigarette smoke on lung
function decline (or determine rate of decline at different stages
of COPD) may be distinct from those which inﬂuence lung
function decline in the general population.26 A small number of
studies have begun to explore interaction between genetic var-
iants and smoking in relation to lung function decline, though
these have not identiﬁed any signiﬁcant associations which also
replicated.35 36
The suggestion that variants which determine lung function
decline may show heterogeneity across different groups is
further supported by ﬁndings from an earlier GWAS which
identiﬁed suggestive evidence that different regions were asso-
ciated with lung function decline in asthmatic and non-asthmatic
individuals. Only the signal in non-asthmatic individuals
(rs9316500 in DLEU7) showed evidence of replication (at
p<0.05) in largely population-based cohorts, but it did not
reach genome-wide signiﬁcance in discovery, replication or two-
stage meta-analysis.27 None of the top variants reported in these
papers reached signiﬁcance after correction for multiple testing
in our data.
Our ﬁndings are also consistent with recent work by Lange
et al37 which identiﬁed two distinct trajectories of FEV1 in
people who developed COPD. In their study, approximately
half of those diagnosed with COPD by the end of follow-up
started with normal lung function in early adulthood (mean age
40) and then showed rapid decline, whereas the remaining half
started with low FEV1 in early adulthood followed by a rela-
tively normal rate of decline. This suggests that rapid lung func-
tion decline in later life is not necessary for development of
COPD. We hypothesise that the known genetic variants exam-
ined in this paper may exert much of their effect in earlier life.
Of the 26 regions examined in this paper, 19 have previously
been shown to have directions of effect on lung function in chil-
dren (aged 7–9 years) consistent with that in adults.8 An add-
itional study has also shown evidence of association with lung
function as early as 5–14 weeks of age for variants in 4 of the
26 loci.38 However, further large GWAS of lung development
are required to test this hypothesis.
These ﬁndings emphasise the continuing public health
importance of focusing on the key environmental determinants
of lung function decline, particularly smoking. Nevertheless,
genetic determinants of decline may remain a therapeutic
target in the half of people with COPD for whom accelerated
decline is important in pathogenesis.37 A potential strategy to
identify these would be to focus on older cohorts and adjust
for the effect of all known variants which affect cross-sectional
lung function. Large sample sizes will also be the key to help
conﬁrm or refute our ﬁndings. However, as the largest existing
meta-analysis identiﬁed signiﬁcant challenges posed by pheno-
typic heterogeneity, ensuring comparability of the participating
studies’ approach to measuring longitudinal change must also
be a high priority. An alternative approach would be to study
longitudinal lung function in large, more homogeneous
populations.
In summary, regions previously identiﬁed as signiﬁcantly
associated with cross-sectional FEV1 and/or FEV1/FVC
5–8 were
Table 2 Weighted risk score in Busselton Health Study (BHS) and Copenhagen City Heart Study (CCHS) for 26 known regions associated with
FEV1 or FEV1/FVC
BHS CCHS
β SE p Value β SE p Value
FEV1, mL (baseline) −13.0 1.97 9.75×10−12 −6.10 1.24 8.92×10−7
FEV1, mL/year (change over time) 0.070 0.085 0.409 −0.13 0.058 0.030
FEV1/FVC (baseline) −2.62×10−3 3.23×10−4 4.44×10−16 −1.28×10−3 2.05×10−4 4.45×10−10
FEV1/FVC (change over time) −2.42×10−5 1.72×10−5 0.160 −1.37×10−5 1.33×10−5 0.302
β, per-allele change in FEV1 or FEV1/FVC.
405John C, et al. Thorax 2017;72:400–408. doi:10.1136/thoraxjnl-2016-208448
Chronic obstructive pulmonary disease
group.bmj.com on July 20, 2017 - Published by http://thorax.bmj.com/Downloaded from 
jointly strongly associated with baseline measurements in both
discovery and replication cohorts but were not associated with
change in FEV1 or FEV1/FVC over time. The present study
and others to date have identiﬁed no regions associated with
lung function decline which reach genome-wide signiﬁcance
and replicate in independent cohorts. Genetic variants identi-
ﬁed to date that inﬂuence cross-sectional lung function, while
still relevant in predicting the risk of COPD, appear to have
Table 3 Variants selected for follow-up and their association with longitudinal change in lung function (FEV1, FVC and FEV1/FVC) in Busselton
Health Study (BHS)
Variant Top variant in region Chr Position Risk allele Other allele Risk allele frequency β SE p Value
(a) FEV1 (mL/year)
rs114969412 rs114969412 1 106234189 G A 0.06 −4.84 1.00 1.29×10−6
rs13099788 rs13099788 3 192286178 C G 0.56 −2.29 0.488 2.75×10−6
rs3819182 rs3819182 4 101107664 A C 0.40 −2.14 0.460 3.47×10−6
rs3113685 rs3113685 4 109982140 G T 0.39 −2.71 0.571 1.98×10−6
rs876365 rs3113685 4 109989467 C T 0.31 −2.19 0.483 5.65×10−6
5:51298598:T_TG 5:51298598:T_TG 5 51298598 I R 0.05 −6.19 1.32 2.97×10−6
rs76575180 5:51298598:T_TG 5 51546441 G T 0.03 −6.72 1.61 3.15×10−5
5:136298545:A_AG 5:136298545:A_AG 5 136298545 I R 0.88 −3.16 0.691 4.91×10−6
rs72901148 rs72901148 6 79562115 A G 0.02 −8.95 1.73 2.15×10−7
rs11158759 rs11158759 14 69162043 C T 0.84 −2.87 0.627 4.73×10−6
rs6502247 rs6502247 17 13203562 G A 0.87 −3.93 0.663 3.23×10−9
rs8073053 rs8073053 17 19553382 A G 0.30 −2.38 0.518 4.41×10−6
rs8132156 rs8132156 21 47062729 A G 0.10 −4.17 0.833 5.72×10−7
rs113301658 rs113301658 22 34148991 C G 0.14 −4.57 0.826 3.21×10−8
(b) FVC (mL/year)
1:44578970:G_GCA 1:44578970:G_GCA 1 44578970 R I 0.98 −10.3 2.10 1.07×10−6
rs878118 rs878118 3 71246228 T G 0.80 −3.39 0.727 3.11×10−6
rs150801948 rs150801948 6 15920550 T C 0.02 −10.0 2.16 3.46×10−6
rs111605394 rs111605394 7 51412802 A T 0.96 −9.11 1.78 2.91×10−7
8:105858623:TTTC_ 8:105858623:TTTC_ 8 105858623 R D 0.19 −3.84 0.818 2.71×10−6
9:424077:TA_T 9:424077:TA_T 9 424077 D R 0.01 −14.8 3.09 1.70×10−6
rs118036814 rs118036814 11 107316060 A G 0.07 −6.43 1.26 3.59×10−7
13:94098659:CT_C 13:94098659:CT_C 13 94098659 D R 0.24 −3.32 0.701 2.18×10−6
rs62028012 rs62028012 15 97946036 C T 0.73 −3.55 0.751 2.26×10−6
rs1862844 rs6539968 16 86758079 C A 0.61 −4.64 0.878 1.24×10−7
rs6539968 rs6539968 16 86759924 C T 0.64 −2.90 0.614 2.30×10−6
18:39303165:GTAGA 18:39303165:GTAGA 18 39303165 R D 0.92 −5.21 1.13 4.35×10−6
rs12965811 rs12965811 18 63173334 T G 0.07 −5.78 1.19 1.16×10−6
rs113179796 rs10404081 19 22748391 C T 0.95 −12.0 2.21 5.17×10−8
rs10404081 rs10404081 19 22756773 A G 0.97 −8.97 1.95 4.25×10−6
rs10404632 rs10404081 19 22763493 T C 0.96 −6.23 1.49 2.89×10−5
rs2740192 rs2740185 20 3059396 C T 0.14 −4.33 0.976 8.98×10−6
rs2740185 rs2740185 20 3061436 A G 0.20 −4.35 0.930 3.00×10−6
(c) FEV1/FVC (change per year)
rs11694877 rs11694877 2 5992517 G T 0.91 −6.43×10−4 1.39×10−4 3.79×10−6
rs72847294 rs72847294 2 88684174 G A 0.07 −7.90×10−4 1.52×10−4 2.14×10−7
rs6434439 rs6434439 2 191997584 A C 0.43 −3.86×10−4 8.43×10−5 4.57×10−6
rs73832306 rs73832306 4 99370515 T C 0.97 −1.13×10−3 2.48×10−4 4.90×10−6
rs10043201 rs116563943 5 1600242 G A 0.77 −4.57×10−4 1.01×10−4 6.03×10−6
rs116563943 rs116563943 5 1606844 G T 0.82 −6.74×10−4 1.45×10−4 3.26×10−6
rs58140608 rs114704427 5 170929096 C T 0.93 −7.19×10−4 1.66×10−4 1.43×10−5
rs114704427 rs114704427 5 170941277 C T 0.98 −1.83×10−3 3.54×10−4 2.18×10−7
rs512976 rs512976 6 7163873 T C 0.15 5.29×10−4 1.14×10−4 3.20×10−6
rs11136718 rs11136718 8 4157216 G A 0.63 −4.22×10−4 9.19×10−5 4.27×10−6
rs4737863 rs4737863 8 68857698 G C 0.45 −3.71×10−4 7.89×10−5 2.56×10−6
rs72671203 rs72671203 14 20673455 G A 0.13 −5.72×10−4 1.18×10−4 1.20×10−6
rs17197324 rs17197324 14 22079359 C G 0.83 −4.94×10−4 1.03×10−4 1.80×10−6
rs117466318 rs117466318 14 82200378 A G 0.97 −1.17×10−3 2.56×10−4 4.60×10−6
rs80245972 rs117466318 14 82205915 C T 0.92 −5.80×10−4 1.43×10−4 4.72×10−5
rs16960347 rs16960347 17 64889056 C T 0.93 −7.21×10−4 1.58×10−4 4.83×10−6
Betas provided correspond to the risk allele. Risk allele here is defined as the allele associated with decreased lung function in BHS.
Variants are given in order of Chr and position.
β, per-allele change in FEV1, FVC or FEV1/FVC; Chr, chromosome.
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little or no effect on the rate of change in adult lung function
over time in our study.
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